DEFERASIROX

deferasirox 250 mg dispersible tablet, 28

DEFERASIROX (6500D)

deferasirox 250 mg dispersible tablet, 28
6500D
Manner of administration:Oral
Private
S100 HSD Private
Authority Required

Restriction

Indication: Chronic iron overload
Treatment phase: Initial treatment

Restriction

Indication: Chronic iron overload
Treatment phase: Initial treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 6 Max qty units: 168 # of repeats: 5 DPMQ: $137.28 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Deferasirox Juno
Pharmacor Deferasirox